Ascendis Pharma A/S (NASDAQ:ASND) Receives $173.88 Average PT from Analysts

Shares of Ascendis Pharma A/S (NASDAQ:ASND) have been assigned an average recommendation of “Moderate Buy” from the eight ratings firms that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $173.88.

A number of research analysts have issued reports on the stock. Wells Fargo & Company raised their price target on shares of Ascendis Pharma A/S from $260.00 to $262.00 and gave the stock an “overweight” rating in a report on Friday, May 3rd. Citigroup increased their price objective on Ascendis Pharma A/S from $146.00 to $182.00 and gave the company a “buy” rating in a report on Thursday, February 8th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $173.00 target price on shares of Ascendis Pharma A/S in a report on Friday, May 3rd. Morgan Stanley reiterated an “equal weight” rating and issued a $116.00 price target on shares of Ascendis Pharma A/S in a report on Monday, April 22nd. Finally, Wedbush upped their price objective on shares of Ascendis Pharma A/S from $207.00 to $225.00 and gave the company an “outperform” rating in a report on Thursday, February 8th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Westfield Capital Management Co. LP lifted its holdings in Ascendis Pharma A/S by 6.0% during the fourth quarter. Westfield Capital Management Co. LP now owns 4,030,634 shares of the biotechnology company’s stock valued at $507,658,000 after purchasing an additional 228,457 shares in the last quarter. Avoro Capital Advisors LLC raised its position in shares of Ascendis Pharma A/S by 2.3% during the 4th quarter. Avoro Capital Advisors LLC now owns 3,755,555 shares of the biotechnology company’s stock worth $473,012,000 after purchasing an additional 85,555 shares during the last quarter. Capital International Investors lifted its stake in Ascendis Pharma A/S by 0.6% in the 4th quarter. Capital International Investors now owns 2,181,268 shares of the biotechnology company’s stock valued at $274,731,000 after buying an additional 12,825 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its holdings in Ascendis Pharma A/S by 20.1% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 1,519,219 shares of the biotechnology company’s stock worth $191,346,000 after buying an additional 254,749 shares during the last quarter. Finally, TimesSquare Capital Management LLC increased its stake in Ascendis Pharma A/S by 9.8% during the 3rd quarter. TimesSquare Capital Management LLC now owns 842,801 shares of the biotechnology company’s stock worth $78,920,000 after buying an additional 75,374 shares in the last quarter.

Ascendis Pharma A/S Stock Performance

Shares of NASDAQ ASND opened at $133.93 on Friday. Ascendis Pharma A/S has a fifty-two week low of $83.75 and a fifty-two week high of $161.00. The company has a market cap of $7.80 billion, a PE ratio of -13.94 and a beta of 0.54. The business has a 50-day simple moving average of $145.55 and a two-hundred day simple moving average of $128.74.

Ascendis Pharma A/S (NASDAQ:ASND) last released its earnings results on Wednesday, February 7th. The biotechnology company reported ($1.66) EPS for the quarter, topping analysts’ consensus estimates of ($2.15) by $0.49. Ascendis Pharma A/S had a negative net margin of 152.68% and a negative return on equity of 16,574.15%. The company had revenue of $148.62 million during the quarter, compared to analysts’ expectations of $97.02 million. On average, sell-side analysts predict that Ascendis Pharma A/S will post -4.15 earnings per share for the current fiscal year.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.